GR

Greatland Resources Limited

A gold and copper producer operating and developing mines in Western Australia's Paterson region.

GGP | IL

Overview

Corporate Details

ISIN(s):
AU0000397705
LEI:
213800KQI75ZGE53GX44
Country:
Australia
Address:
LEVEL 3, 502 HAY STREET, 6008 SUBIACO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Greatland Resources Limited is a gold and copper producer engaged in the discovery, development, extraction, and processing of precious and base metals. The company's principal assets are located in the Paterson region of Western Australia. It operates the Telfer gold-copper mine, a large-scale mining complex with significant processing infrastructure. Concurrently, Greatland is developing the nearby high-grade Havieron gold-copper project, which is designed to utilize the existing Telfer facilities for ore processing. The company also maintains a substantial exploration portfolio in the region. Greatland's strategy is to become a profitable multi-mine resources company through responsible and sustainable operations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 10:30
Post-Annual General Meeting Information
Results of 2025 Annual General Meeting
English 11.1 KB
2025-11-13 09:35
Post-Annual General Meeting Information
Headline: 2025 AGM - Chairman's Address
English 14.5 KB
2025-11-10 09:35
Major Shareholding Notification
Holding(s) in Company
English 108.6 KB
2025-10-27 10:45
Major Shareholding Notification
Holding(s) in Company
English 102.8 KB
2025-10-23 08:46
Report Publication Announcement
September 2025 Quarter Results
English 13.2 KB
2025-10-22 09:52
Regulatory News Service
September 2025 Quarter Drilling Update
English 20.2 KB
2025-10-10 09:42
Investor Presentation
Corporate Presentation
English 10.9 KB
2025-10-10 08:55
Pre-Annual General Meeting Information
2025 Notice of Annual General Meeting
English 11.9 KB
2025-10-09 08:00
Board/Management Information
Appointment of Joint Corporate Broker
English 11.2 KB
2025-10-07 08:00
Earnings Release
September 2025 Quarter Production Update
English 14.6 KB
2025-09-26 08:44
Remuneration Information
Director/PDMR Shareholding
English 32.6 KB
2025-09-25 08:24
Report Publication Announcement
2025 Annual Report
English 11.0 KB
2025-09-18 09:28
Major Shareholding Notification
Holding(s) in Company
English 107.6 KB
2025-08-28 12:11
Annual Report
Unaudited Prelim FY25 Final Report - Replacement
English 681.4 KB
2025-08-28 09:05
Earnings Release
Unaudited Preliminary FY25 Final Report
English 681.5 KB

Automate Your Workflow. Get a real-time feed of all Greatland Resources Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greatland Resources Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greatland Resources Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.